Legal Representation
Attorney
R. Neil Sudol
USPTO Deadlines
Application History
23 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Oct 29, 2018 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Oct 29, 2018 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Mar 20, 2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Mar 16, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Mar 16, 2018 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Mar 16, 2018 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Sep 5, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Sep 1, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Sep 1, 2017 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Sep 1, 2017 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
May 1, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Mar 28, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Jan 31, 2017 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Jan 31, 2017 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Jan 11, 2017 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Dec 19, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Dec 14, 2016 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Dec 14, 2016 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Dec 14, 2016 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Dec 14, 2016 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Dec 10, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Sep 8, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Sep 5, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, lipid vesicles encapsulating pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, vesicles made of cholesteryl ester and containing pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis, and vaccines and vaccination to prevent or treat infectious diseases and cancer
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005